Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

7.330 -0.370 (-4.81%)
Streaming Delayed Price Updated: 10:51 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
What Patients Need to Know About the Remission Rate of Glioblastomas
Via Investor Brand Network
Scientists Uncover Possible Driver of ‘Chemo Brain’
Via Investor Brand Network
Virtual Brain Tumors Could Transform How Cancer is Treated
Via Investor Brand Network
New AI Tool Boosts Precision Medicine in Treating CNS Cancers
Via Investor Brand Network
Topics Artificial Intelligence
Scientists Stunned Upon Discovering Glioblastoma Erodes Skull Tissue
Via Investor Brand Network
Scorpion Venom Shows Promise in Brain Tumor Treatment
Via Investor Brand Network
Rogue Rings of DNA Expose Brain Tumor Secrets
Via Investor Brand Network
New Research Suggests Dietary Change Could Improve Glioblastoma Treatment Outcomes
Via Investor Brand Network
NCI Halts Funding for Consortium Conducting Trials on Childhood Brain Cancers
Via Investor Brand Network
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Via ACCESS Newswire
Study Finds Link Between Head Injuries and Elevated Brain Cancer Risk
Via Investor Brand Network
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Drug Development and Market Potential on BioMedWire Podcast
Via Investor Brand Network
Blocking Glioblastoma-Triggered Brain Damage Could Slow the Aggressive Tumor’s Growth
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial
Via Investor Brand Network
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series
Via Investor Brand Network
What Women Need to Know About Benign Brain Tumors
Via Investor Brand Network
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Via ACCESS Newswire
Study Reveals Potential Way to Treat Pediatric Gliomas
Via Investor Brand Network
Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment
Via Investor Brand Network
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Virtual Investor Summer Spotlight Conference
Via Investor Brand Network
Unexpected Finding Potentially Opens the Door to Universal Vaccines Against Cancer
Via Investor Brand Network
CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
Via ACCESS Newswire
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Via ACCESS Newswire
New Machine Learning Model Predicts Cancer Severity, Aids Treatment Planning
Via Investor Brand Network
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22
Via Investor Brand Network
CNS Pharmaceuticals Announces Reverse Stock Split
Via ACCESS Newswire
New Study Suggests Concussions Could Lead to Higher Risks of Brain Cancer
Via Investor Brand Network
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Lead Program in Virtual CEO Segment
Via Investor Brand Network
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.